Publications by authors named "M V Jorda"

Castration-resistant prostate cancer (CRPC) is incurable and fatal, making prostate cancer the second leading cancer-related cause of death for American men. CRPC results from therapeutic resistance to standard-of-care androgen deprivation (AD) treatments, through incompletely understood molecular mechanisms, and lacks durable therapeutic options. In this study, we identified enhanced soluble guanylyl cyclase (sGC) signaling as a mechanism that restrains CRPC initiation and growth.

View Article and Find Full Text PDF

Urine cytology is a non-invasive, cost-efficient, and sensitive test to detect high-grade urothelial carcinoma. The Paris System (TPS) for Reporting Urinary Cytology is an evidence-based system that uses the risk of malignancy to guide patient management. Since its inception, TPS has standardized urine cytology reports, facilitating communication among pathologists and between pathologists and clinicians.

View Article and Find Full Text PDF

Context: Medical treatment of acromegaly is currently performed through a trial-and-error approach using first-generation somatostatin receptor ligands (fgSRLs) as first-line drugs, with an effectiveness of about 50%, and subsequent drugs are indicated through clinical judgment. Some biomarkers can predict fgSRLs response.

Objective: Here we report the results of the ACROFAST study, a clinical trial in which a protocol based on predictive biomarkers of fgSRLs was evaluated.

View Article and Find Full Text PDF

Introduction: Growth hormone (GH)-secreting pituitary tumors (GHomas) are the most common acromegaly cause. At diagnosis, most of them are macroadenomas, and up to 56% display cavernous sinus invasion. Biomarker assessment associated with tumor growth and invasion is important to optimize their management.

View Article and Find Full Text PDF
Article Synopsis
  • - The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) suggests that atypia of undetermined significance (AUS) should not exceed 10%, but some recent findings indicate that it might often be overused, especially when molecular testing results are low.
  • - A study analyzed the cytology cases over 4.5 years, examining AUS rates and positive call rates for different cytopathologists, revealing a wide range of AUS rates (from 9.9% to 36.8%) and an overall positive call rate of 24%.
  • - The findings suggest that monitoring AUS rates alongside positive call rates can provide a valuable way to evaluate and enhance the performance of cytology labs and individual cytopath
View Article and Find Full Text PDF